Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention
Completed
Mohamed Abdelfatah
Phase 4
2020-03-15
Investigate of the potential benefit of acute pretreatment with high dose atorvastatin (80
mg) in reduction of the incidence of CIN in diabetic patients indicated for elective coronary
intervention.
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Recruiting
Breast Cancer Research Foundation
Phase 1
2020-10-13
The purpose of the study is identify the dose(s) of infigratinib to use in combination with
tamoxifen to treat patients with a particular type of advanced breast cancer (hormone
receptor-positive, HER2-negative, FGFR-altered breast cancer)
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Recruiting
National Cancer Institute (NCI)
Phase 1
2020-10-13
The purpose of the study is identify the dose(s) of infigratinib to use in combination with
tamoxifen to treat patients with a particular type of advanced breast cancer (hormone
receptor-positive, HER2-negative, FGFR-altered breast cancer)
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Recruiting
QED Therapeutics, Inc.
Phase 1
2020-10-13
The purpose of the study is identify the dose(s) of infigratinib to use in combination with
tamoxifen to treat patients with a particular type of advanced breast cancer (hormone
receptor-positive, HER2-negative, FGFR-altered breast cancer)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.